Opinion

Video

Optimizing BTKi Treatment Strategies

The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.

The group discusses anticipated advancements in Bruton tyrosine kinase inhibitor (BTKi) therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A key goal is converting continuous BTKi treatment into time-limited approaches through combinations or stopping criteria based on deep responses. This could improve quality of life and reduce financial burdens compared with indefinite therapy.Incorporating assessment of minimal residual disease as a trigger for discontinuation is an exciting strategy being explored in trials.

The panelists highlight the potential of leveraging precision medicine through mutational profiling and cytogenetics to guide upfront BTKi selection and sequencing. This allows customization based on a patient’s molecular features rather than a one-size-fits-all approach. Expanding the options for noncovalent BTKis that can overcome specific resistance mutations will enable optimal treatment sequencing tailored to a patient’s mutational profile when disease relapse occurs.

Overall, the group is optimistic about integrating predictive biomarkers, combination strategies, and novel targeted agents to usher in an era of personalized BTKi therapy in CLL and SLL. This offers hope for maximizing treatment outcomes while minimizing toxicity burdens for patients.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo